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Abstract: Introduction: Deep vein thrombosis (DVT) is a common disease with serious risks such as pulmonary embolism
and there are different anticoagulant therapies for treatment of this condition. In this study, we investigated
the association between the duration of hospitalization with different treatment methods and comorbidities.
Materials and methods: In this retrospective cross-sectional study, the hospital records of 213 patients with a
diagnosis of acute DVT in Shohada-e-Tajrish Hospital in 2019 and 2020 were reviewed. Patients were divided
into five main groups and five subgroups based on the type of treatment. Then, the association between the
duration of hospitalization and different treatment methods was studied. Results: Treatment with novel oral
anticoagulants (NOACs) with an average length of 2.5 days of hospitalization significantly reduces the duration
of hospitalization. Combination therapy with low molecular weight heparin (LMWH) and warfarin or LMWH
alone, with an average of 8.38 and 8.20 days, is preferable to treatment with unfractionated heparin (UFH) and
warfarin, with an average of 9.2 days. Warfarin treatment with an average duration of hospitalization of 8.43
days is in the third place. The use of other methods has increased the duration of hospitalization. History of
comorbidities including history of hospitalization, hypertension, smoking, cancer and trauma are the five co-
morbidities that have the greatest effect on the length of hospitalization of patients, respectively. Conclusion:
According to the present study, treatment with NOACs reduces the duration of hospitalization of patients more
than the other treatment methods. The second best choice is LMWH injection therapy and continuation with
warfarin or starting and continuing treatment with LMWH preferable to injecting treatment with UFH and con-
tinuing with warfarin. The type of underlying disease and comorbidities had a significant effect on the duration
of hospitalization.
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1. Introduction
DVT and pulmonary thromboembolism (PTE) are part of the
spectrum of venous thromboembolism (VTE), which is the
third leading cause of death from cardiovascular disease af-
ter myocardial infarction and stroke. (1) Classic clinical signs
include edema, limb pain, tenderness, warmth, and ery-
thema of the skin around the site of thrombosis, respectively.
Due to the asymptomatic nature of many DVTs that occur in
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the hospital, the clinical diagnosis is unreliable. Therefore
in addition to clinical scoring systems, ultrasound and D-
Dimer measurement can be used. Long-term side effects in-
clude recurrent VTE, pulmonary embolism, chronic throm-
boembolic pulmonary hypertension and post thrombotic
syndrome (PTS). (2, 3) Nine studies of hospital records and
Asian databases reported VTE rates ranging from 11 to 88 per
10,000 admissions. Population-based estimates for postop-
erative DVT rates range from 0.15 to 1.35 percent. The elderly
are at higher risk of DVT and VTE. (4) Malignancies, preg-
nancy, OCP or HRT use during menopause, obesity, surgery,
trauma, antiphospholipid syndrome, systemic hypertension,
COPD, chronic kidney disease, prolonged air travel, blood
transfusion, smoking, and air pollution are some of the most
common predisposing factors of thrombosis. (5, 6) Due to
lifestyle changes and increased immobility, obesity, chronic
diseases and cancers will have an increase in incidence in the
future. Early diagnosis and treatment of DVT is important
and reduces complications such as post-phlebitis syndrome
and mortality.
In general, VTE treatment is divided into two categories of
primary therapy, including thrombolytic or embolectomy
and secondary therapy, including anticoagulants and IVC fil-
ter implantation. The basis of VTE treatment is anticoagu-
lants, but the primary method is used for extensive femoral
or iliofemoral thrombosis, DVT of the upper extremities or
high-risk patients with pulmonary embolism. Anticoagu-
lants are used to prevent and treat DVT, which prevent clots
from forming or spreading by blocking the coagulation fac-
tors’ action. (6) NOACs, including factor Xa inhibitors witch
as apixaban, edoxaban, and rivaroxaban, and thrombin in-
hibitors such as dabigatran have been studied in phase three
studies in a wide range of thromboembolic disorders (7). The
addition NOACs to the pharmacopoeia is one of the most im-
portant recent advances in DVT management. Its use has
been considered worldwide, although drug selection, recur-
rence, and chronic therapeutic effects are discussed. Exten-
sive studies are underway to evaluate the effect of NOACs
on disease complications such as recurrent thrombosis and
post-phlebitis syndrome (PTS) (8, 9). Common anticoagu-
lants such as VKAs, UFH, LMWH have been used for decades
but they increase the risk of bleeding. Therefore, NOACs
drugs include direct inhibitors of thrombin and direct in-
hibitors of factor Xa, which have many advantages over con-
ventional drugs, such as rapid impact, low drug and food
interactions, no need for routine monitoring such as INR
checks, also they have better patient compliance and similar
or better efficacy and safety than heparin or VitK antagonists.
(10)
In choosing the treatment method of VTE and the type of
anticoagulant, factors such as patient’s age, risk of bleed-
ing, history of surgery and comorbidities such as cancer, and
kidney failure should be considered. Therefore, the clinical
benefits of an anticoagulant should be ideally balanced with
the risks associated with treatment (7). DVT treatment algo-
rithms have made great progress in recent years; yet it is nec-
essary to review and compare traditional and new therapies.
On the other hand, the economic burden of DVT and PTE on
direct medical costs is very high. This is due to the initial hos-
pitalization of patients as well as the readmission of patients
(5% -14%), more than half of which occur within 90 days. (11)
And due to the existing limitations such as hospital beds and
human resources and different therapeutic effects of differ-
ent methods, choosing the optimal method is important ac-
cording to the length of hospitalization of patients.
In a 2018 study by Karl E Minges et al., 726,423 patients
were admitted from 1999 to 2010 for DVT. In general, the
rate of hospitalization in DVT has decreased except in black
patients. This decrease has been attributed to changes in
treatment protocol and increase in outpatient treatment and
faster transfer of hospitalized patients to continue outpatient
treatment. (12)
Therefore, in the present study, we decided to examine the
patients admitted to Shohada-e-Tajrish Hospital who were
hospitalized with this diagnosis during 2019 and 2020 in
terms of the length of their hospitalization, and evaluate its
association with the type of treatment used and the type of
comorbid diseases.
2. Materials and Methods
In this retrospective study, the medical records of 213 pa-
tients (122 men, 56.8%) admitted with diagnosis of acute
DVT confirmed with Doppler ultrasonography in Shohada-
e-Tajrish Hospital in 2019 and 2020 were used to investigate
the duration of hospitalization and its association with treat-
ment and the comorbidities of the patients. The study was
approved by the ethics committee, and Due to Helsinki con-
vention, name and personal information of the patients will
remain confidential with the researchers, all reports will be
generalized and nameless.
After receiving the permission of the hospital ethics commit-
tee, questionnaires were designed to collect patients’ infor-
mation from their medical records including general infor-
mation of the patient, history and clinical findings, labora-
tory and paraclinical findings of the patient, the treatment
method used during hospitalization and after discharge, and
the presence of comorbidities including ischemic heart dis-
ease (IHD), Dyslipidemia (DLP), hypertension (HTN), benign
prostatic hyperplasia (BPH), diabetes mellitus (DM), cancer,
chronic obstructive pulmonary disease (COPD), cancer, obe-
sity, history of hospitalization, history of surgery, trauma,
smoking or oral contraceptives (OCPs) use.
Patients were divided into five main groups and five sub-
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groups based on the type of anticoagulant treatment used.
The 5 main treatment groups included: NOAC treatment, ini-
tiation of injection therapy with UFH and continuation with
warfarin, initiation of injection therapy with LMWH and con-
tinuation with warfarin, initiation of treatment with UFH and
continuation with LMWH and initiation of treatment with
UFH and continuation with LMWH. Subgroup groups in-
cluded: untreated group, mechanical treatment with IVC fil-
ter, initiation and continuation of treatment with UFH, con-
tinuation of warfarin treatment in patients with relapse who
were treated and the use of different anticoagulants (table 1).
Mean and standard deviation were used to describe quan-
titative variables and number and percentage was used for
qualitative variables. The Mann-Whitney method was used
to evaluate the effect of patients’ gender on the length of hos-
pital stay. Data distribution was assessed by X2 test. Due
to the small number of samples and their abnormal distri-
bution, Kruskal-Wallis test (H test) was used to compare the
duration of patients’ hospitalization in different treatment
groups. Mann-Whitney test (U test) was used to compare two
groups of patients with and without comorbidities. To inves-
tigate the effect of the type of comorbidities on the duration
of hospitalization, Friedman’s test was used.
SPSS software version 20 was used for statistical analysis of
data. P values of 0.05 or less were considered statistically sig-
nificant.
3. Results
In this study, 213 patients who were hospitalized with a diag-
nosis of acute DVT were studied, including 122 (56.8%) males
and 91 (43.2%) females, with a mean age of 57.86±19.63.
According to the table 2, 71.8% of patients with DVT pre-
sented with typical symptoms of the disease, including
swelling, pain and limb erythema, and 28.2% of patients were
hospitalized due to other common diseases, and finally the
diagnosis of DVT was made. The most common in terms of
frequency are loss of consciousness (LOC) with 9%, weakness
with 2.8% and shortness of breath with 2.8%, respectively.
Our results showed that gender has no significant effect on
length of hospital stay (P value = 0.283). Days of hospital
stay in different treatment groups are mentioned in table 3
and the results showed that the treatment method has a sig-
nificant effect on the length of hospital stay of patients with
DVT (P value=0.014) (Diagram 1). Among all of the patients,
101 patients did not have any of the comorbidities consid-
ered in the study and 112 had at least one. Mann-Whitney
test showed that having comorbidities is significantly asso-
ciated with the length of hospital stay (P value=0.017). The
type of comorbidity has a significant and variable effect on
the duration of hospitalization (P value<0.001) (Table 4). In
addition, five comorbidities which have the greatest effect on
patients’ duration of hospitalization are respectively the his-
tory of hospitalization, recent history of surgery, hyperten-
sion, smoking and cancer.
4. Discussion
The aim of this study was to evaluate the duration of hospi-
talization and its relationship with the treatment used and
comorbidities in patients admitted with acute DVT diagno-
sis. From the statistical analysis of the obtained results, it
can be concluded that gender has no significant effect on
the duration of hospitalization of patients, while the pres-
ence of the comorbidities have an effect on the length of hos-
pitalization. Also, the type of treatment affects the duration
of the patient’s hospitalization, in a way that treatment with
NOACs has the shortest duration of hospitalization and in
the next ranks are injectable treatment with LMWH or start
treatment with LMWH and continue with warfarin, continue
warfarin treatment in patients who already have INR impair-
ment and have been treated with warfarin, start treatment
with UFH and continue with oral warfarin treatment, in-
stallation of IVC filter, using the mix method means starting
with UFH, switching to LMWH and continuing with warfarin,
UFH treatment alone and start treatment with UFH and con-
tinue with LMWH, respectively.
In the study of Y. Hong et al., Which was a systematic re-
view of randomized control trials, 4064 patients were studied.
In this study, the effect of anticoagulant therapy on the rate
of hospitalization and duration of hospitalization in patients
with DVT was investigated. Results of this study depict that,
patients treated with LMWH were hospitalized 33% less than
UFH and the mean difference in duration of hospitalization
between LMWH and UFH was 2.54 days. Also, the duration of
hospitalization of patients receiving rivaroxaban was signifi-
cantly reduced compared to injectable treatments, in a way
that this difference was reported 1-5 days for VTE, 3 days for
DVT and 1 day for PE. These findings confirm the results of
our research. (1)
In an observational study, R. Morillo et al., assessed the hos-
pitalization process and the use of interventional therapies
among 26,695 patients with DVT between 2001 and 2014. The
average duration of hospitalization decreased from 9.0 days
in 2001 to 2005 to 7.6 days in 2010 to 2014, and the rate of
LMWH use at the start of DVT treatment decreased from 98%
to 90%, while DOACS consumption increased from 0.5% in
2010 to 13.4% in 2014. (13)The findings of this study also
show the effect of DOACs on reducing the duration of hos-
pitalization of patients.
In a study by K. E. Minges et al. in 2018, 726,423 patients
were admitted from 1999 to 2010 for DVT. In general, the rate
of hospitalization in DVT has decreased, except in patients
with African origin. This decrease has been attributed to the
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change of treatment protocol and the increase of outpatient
treatment and faster transfer of hospitalized patients to con-
tinue outpatient treatment. (12)
In a 2019 retrospective study by E. R. Pritchard et al., Can-
cer patients treated with DOACs, LMWH, or Vit K antagonists
had an equal risk for major bleeding, with gastrointestinal
bleeding being the most common event. The risk of recur-
rence of VTE in DOACs and LMWH groups was higher com-
pared to previous studies. (14) The difference between the
results of this article and our study can be attributed to the
focus of this study on cancer patients who may respond dif-
ferently to anticoagulant therapy.
A 2009 study by N. Isma et al. Examined risk factors and the
distribution of VTE. Of the 1140 patients with VTE in 1998-
2006, 49% were male and 51% were female. 882 patients had
DVT, 330 had PE and 72 had DVT / PE. The most common
acquired risk factor for VTE was hormone therapy. Immo-
bility, history of surgery, cancer and family history were also
observed in these patients, respectively. (15)
One of the limitations of this study is the retrospective nature
of it, so it is not possible to intervene in patients and evalu-
ate changes. Also, oral therapies were not widely used in the
years 94 to 95, and therefore the number of samples was not
evenly distributed and more accurate comparisons were not
possible.
In order to better compare the treatment methods, we
propose a prospective study with the aim of examin-
ing acute complications such as disease recurrence and
bleeding within 90 days after treatment, mortality, post-
thrombophlebitis syndrome and the degree of patients’ co-
operation in taking drugs. Further specific studies are also
needed to evaluate the efficacy and safety of anticoagulants,
especially NOACs, for the treatment of DVT in specific pa-
tient populations, including the elderly, obese, and cancer
patients.
5. Conclusion
NOACs, including direct thrombin inhibitors and direct fac-
tor Xa inhibitors, have many advantages over older drugs. Ac-
cording to the present study, treatment with these drugs sig-
nificantly reduces the duration of hospitalization of patients.
History of comorbidities including history of hospitalization,
hypertension, smoking, cancer and trauma are the five co-
morbidities that have the greatest effect on the duration of
hospitalization of patients, respectively. Because of these co-
morbidities that cause DVT, it is important to consider pro-
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Table 1: Frequency distribution of different treatment groups of the study.
Frequency Percent Valid Percent Cumulative Percent
untreated group 6 2.8 2.8 2.8
NOAC 4 1.9 1.9 4.7
UFH to Warfarin 93 43.7 43.7 48.4
LMWH 24 11.3 11.3 59.6
UFH 4 1.9 1.9 61.5
LMWH to Warfarin 50 23.5 23.5 85.0
IVC Filter 5 2.3 2.3 87.3
different anticoagulants 8 3.8 3.8 91.1
UFH to LMWH 12 5.6 5.6 96.7
Warfarin 7 3.3 3.3 100.0
Total 213 100.0 100.0
Table 2: The frequency of primary cause of hospitalization of patients with deep vein thrombosis.
Frequency Percent Valid Percent Cumulative Percent
DVT signs 153 71.8 71.8 78.9
Dyspnea 6 2.8 2.8 81.7
LOC 9 4.2 4.2 92.5
Weakness 6 2.8 2.8 100.0
Total 213 100.0 100.0
Table 3: The mean of hospital stay (days) in different treatment groups.
Treatment groups Mean N Std. Deviation
Untreated group 19.83 6 30.189
NOAC 2.50 4 1.732
UFH to Warfarin 9.80 93 7.376
LMWH 8.38 24 5.273
UFH 12.50 4 7.853
LMWH to Warfarin 8.20 50 4.267
IVC Filter 9.60 5 6.986
different anticoagulants 10.63 8 6.278
UFH to LMWH 14.08 12 6.445
warfarin 8.43 7 3.645
Total 9.68 213 7.996
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Figure 1: The green bar shows the number of patients in each treatment group and most of the patients underwent treatment with UFH to
warfarin. Mean days of hospital stay in each treatment group in showed with blue column and the least was seen in patients treated with NOAC.
This open-access article distributed under the terms of the Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0).
Downloaded from: www.jmp.iums.ac.ir
